Inhibition of ABCG2 by SCO-101 Enhances Chemotherapy Efficacy in Cancer.

ABSTRACT: Chemotherapy resistance, particularly multidrug resistance (MDR), remains a significant barrier to effective cancer treatment, leading to high mortality rates. The development of novel therapeutic strategies targeting key molecular mechanisms to counteract drug resistance is thus an urgent clinical need. In this study, we evaluated the potential of the small molecule SCO-101 to restore chemotherapy sensitivity in drug-resistant cancer cells. Using in silico and in vitro models such as molecular docking, cell viability, colony formation, dye efflux, transporter assays and chemotherapy retention, we assessed the impact of SCO-101 on drug retention and response in several drug-resistant cancer cells. SCO-101 was found to inhibit the activity of breast cancer resistance protein (BCRP/ABCG2) an

SUBMITTER: Pfeiffer A 

PROVIDER: S-EPMC12027554 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature